Page 6,421«..1020..6,4206,4216,4226,423..6,4306,440..»

EPDA Launches Third and Final Life With Parkinson's Booklet to Help Improve the Everyday Lives of People With …

Posted: Published on October 8th, 2012

AMSTERDAM, October 8, 2012 /PRNewswire/ -- Launch helps mark the voluntary organisation's 20thanniversary celebrations in Amsterdam The European Parkinson's Disease Association (EPDA) has launched the third and final booklet in its Life with Parkinson's series. This latest edition concludes a four-year awareness campaign, which aims to highlight the lack of understanding and knowledge concerning Parkinson's that exists throughout Europe today. The booklet's launch, in Amsterdam, the Netherlands, was one of the many activities in a weekend dedicated to celebrating the organisation's 20th anniversary year and its commitment to improving the lives of people with Parkinson's (PwPs). To view the Multimedia News Release, please click: http://www.multivu.com/mnr/56619-epda-launches-life-with-parkinsons-booklet The Life with Parkinson's awareness campaign began in 2008 and the accompanying booklet series has since achieved Europe-wide acclaim from the Parkinson's community, with people living with the disease and healthcare professionals praising the EPDA for its work. "We say that our condition and feelings are impossible to communicate, but this booklet persuaded me that there is a way to share our situation with others," said Bohumila indelov, a PwP from the Czech Republic. "I have to praise all the booklets," added Olga Bandelj, a PwP from Slovenia. "They are very useful. I use them … Continue reading

Posted in Parkinson's Treatment | Comments Off on EPDA Launches Third and Final Life With Parkinson's Booklet to Help Improve the Everyday Lives of People With …

Midnight Walk to help Georgia campaign

Posted: Published on October 8th, 2012

Buy photos Deputy manager Kelly Taylor, Sophie Harper, three, Scruff, Charlie Jelfs, two, and nursery nurse Claire Bruce help raise funds for Georgia. Picture by Marcus Mingins 3912014MMR A NINE-mile Midnight Walk will be held next Friday (October 5) to raise funds for Hope for Georgia - the campaign to raise 20,000 to send Bromsgrove girl Georgia Almquest to America for specialist stem cell treatment. Georgia, who is two next month, has cerebral palsy, which means she is unable to hold her head up, sit or crawl. The stem cell procedure will improve her quality of life and is her only chance of walking. Next Fridays walk will start at McDonalds in Wychbold and go from there to the Castle Nursery, based at BHI Parkside, and back again. The event has been organised by Claire Bruce from Castle Nursery and will conclude a whole week of events which are being held there. On Monday (October 1), there will be a pyjama party for staff and children and on Tuesday (October 2) there will be a bake off where each of the nurserys rooms will compete against each other. The cakes will be sold off at the end for the cause. … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Midnight Walk to help Georgia campaign

Amarantus BioSciences and RBCC Target NuroPro Parkinson's Diagnostic for Joint Venture

Posted: Published on October 8th, 2012

SUNNYVALE, Calif., and NOKOMIS, Fla., Oct. 8, 2012 /PRNewswire/ --Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injury ("TBI") centered on its proprietary anti-apoptotic therapeutic protein MANF, and Rainbow Coral Corp. (RBCC) biotech subsidiary Rainbow BioSciences, have selected NuroPro, Amarantus' Parkinson's disease blood test in development to diagnose symptomatic and asymptomatic Parkinson's sufferers, as the target product candidate for the proposed joint venture ("JV"). The pending JV agreement will see the two entities partner towards the commercialization of NuroPro. "This is a cutting edge approach to diagnosing a debilitating disease that afflicts millions of people worldwide," said RBCC CEO Patrick Brown. "The marketplace is crying out for new breakthroughs in the diagnosis of neurological diseases, and we believe NuroPro has the potential to accurately diagnose people who suffer from Parkinson's disease, allowing physicians to initiate treatment regimens earlier, as well as conduct clinical research on disease-modifying treatments in development on a younger population of patients." The deal is being structured to enable completion of the final stages of the NuroPro program, resulting in a commercially viable product to be introduced to the market place. NuroPro is being developed for … Continue reading

Posted in Brain Injury Treatment | Comments Off on Amarantus BioSciences and RBCC Target NuroPro Parkinson's Diagnostic for Joint Venture

New Data Presented at the 28th ECTRIMS Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research

Posted: Published on October 8th, 2012

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) today announced that key data from the Companys multiple sclerosis (MS) franchise will be featured at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13, 2012. Data presentations will provide new insights on COPAXONE (glatiramer acetate injection), the worlds leading relapsing-remitting multiple sclerosis (RRMS) treatment, and Tevas investigational oral compound laquinimod, as well as results from the ongoing TOP MS and NARCOMS studies. "For more than 20, years Teva has been at the forefront of MS research and development focused on providing effective and safe treatments aimed at meeting the needs of patients living with this complex, often debilitating disease, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. The data being presented at ECTRIMS demonstrate our ongoing commitment to enhancing the treatment experience for RRMS patients and advancing science to assist neurologists in making appropriate treatment decisions, especially as the market continues to evolve. In addition to the data being presented at the Congress, Teva will host a satellite symposium, New Concepts in MS Pathology Shed Light on MS Treatment Approaches on Thursday, … Continue reading

Posted in MS Treatment | Comments Off on New Data Presented at the 28th ECTRIMS Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research

Fundraiser scheduled for Hayden Despenas

Posted: Published on October 8th, 2012

MASON CITY An event to help raise funds for treatment for 9-year-old Hayden Despenas of Mason City, who has been diagnosed with a rare form of muscular dystrophy, is planned Saturday, Nov. 3, in Mason Citys Central Park. Hayden was diagnosed in May with Friedreichs Ataxia, a rare, genetic neurodegenerative disease. Symptoms include loss of muscle strength and coordination; impaired hearing, speech and vision; scoliosis; diabetes and heart disease. 5K and 10K Haydens Hope Warrior Runs will begin at 9 a.m. and will run through the streets and historical areas in Mason City. Individual and team sprint runs will begin at 11 a.m. Food vendors, live music, silent auction and a kids carnival are also planned. Smoked pork sandwiches, hamburger and hot dog meals will be sold. Drink specials will be available at downtown bars. A silent auction will be in the ballroom of the Historic Park Inn. A raffle for a weeks stay on Hilton Head Island in South Carolina will be held. The event was planned in part to raise awareness of Friedreichs Ataxia, as well as to raise funds for research supported by the MDA and Friedreichs Ataxia Research Alliance and to help Hayden participate in encouraging … Continue reading

Comments Off on Fundraiser scheduled for Hayden Despenas

JCI early table of contents for October 8, 2012

Posted: Published on October 8th, 2012

Public release date: 8-Oct-2012 [ | E-mail | Share ] Contact: Jillian Hurst press_releases@the-jci.org Journal of Clinical Investigation Sinusitis: Leaving a bad taste in your mouth The immune system protects the upper respiratory tract from bacterial infections, but the cues that alert the immune system to the presence of bacteria are not known. In this issue of the Journal of Clinical Investigation, researchers led by Noam Cohen at the University of Pennsylvania demonstrated that the bitter taste receptor T2R38 regulates the immune defense of the human upper airway. Cohen and colleagues found that T2R38 was expressed in the cells that line the upper respiratory tract and could be activated by molecules secreted by Pseudomonas aeruginosa and other bacteria. Additionally, they found that common polymorphisms in the T2R38 gene were correlated with the incidence of bacterial sinus infections. These results demonstrate that genetic variation contributes to individual differences in susceptibility to respiratory infection. In a companion piece, Alice Prince of Columbia University discusses the role of bitter taste receptors in immune defense. TITLE: T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection AUTHOR CONTACT: Noam Cohen Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Phone: 215-823-5800 … Continue reading

Comments Off on JCI early table of contents for October 8, 2012

British scientist wins Nobel Prize for Stem Cell work – Video

Posted: Published on October 8th, 2012

08-10-2012 10:32 British scientist Sir John Gurdon, along with Shinya Yamanaka from Japan, have jointly been awarded the Nobel prize for medicine for their work on stem cell research. Their research has uncovered a way to transform adult cells to an embryonic-like stage, that could lead in the future to damaged body tissue being able to be regrown. Gurdon held a news conference in London to discuss the research he has been working on for over 50 years. "In the 1950's we really didn't know whether all your different cells had the same genes or they don't and that was the purpose of the experiments I was doing. And the outcome was that they do. So that means that in principle you should be able to derive any one kind of cell from another, because they have all got the same genes, that was I think the contribution I made at that time," he said. Gurdon also joked that at school he was told by his teachers to stop studying science. He said, "I was at a school where you did no science until the age of 15, and then I did one term of science and then the schoolmaster … Continue reading

Posted in Stem Cell Research | Comments Off on British scientist wins Nobel Prize for Stem Cell work – Video

Stem Cell Research at The Parkinson’s Institute – Video

Posted: Published on October 8th, 2012

04-10-2012 14:05 What is a stem cell? How are they made? How does The Parkinson's Institute use them to push towards a cure for Parkinson's disease? We are pleased to share with you the work of The Schuele and Nichols Laboratories at The Parkinson's Institute. Drs. Schuele and Nichols answer these questions, talk about their laboratory work and share how it's making a difference in the PD world. To learn more about the Schuele or Nichols lab, visit our website at http://www.thepi.org. Follow this link: Stem Cell Research at The Parkinson's Institute - Video … Continue reading

Posted in Stem Cell Research | Comments Off on Stem Cell Research at The Parkinson’s Institute – Video

Government urged on stem cell legislation

Posted: Published on October 8th, 2012

The organisation said the lack of regulation is damaging investment and job creation in the area, and is making Ireland less competitive. Embryonic stem cell research is controversial because it uses cells from human embryos. However, adult stem cells are increasingly being used in research. Meanwhile, the Nobel prize for medicine went to two stem cell researchers from Japan and the UK. John Gurdon of the Gurdon Institute in Cambridge and Shinya Yamanaka of Kyoto University, discovered ways to create tissue that would act like embryonic cells, without the need to collect the cells from embryos. The Nobel committee said their work had revolutionised science. Stem cells have shown huge potential for the development of treatments for a range of conditions, including Parkinson's Disease, heart disease, strokes and spinal cord damage. As far back as 1962, Mr Gurdon became the first scientist to clone an animal, making a healthy tadpole from the egg of a frog with DNA from another tadpole's intestinal cell. That showed that developed cells carry the information to make every cell in the body - decades before other scientists made world headlines by cloning the first mammal from adult DNA, Dolly the sheep. More than 40 … Continue reading

Posted in Stem Cell Research | Comments Off on Government urged on stem cell legislation

Stem Cell Science Q & A

Posted: Published on October 8th, 2012

Shinya Yamanaka MD, PhD What are induced pluripotent stem cells? Induced pluripotent stem cells, or iPS cells, are a type of cell that has been reprogrammed from an adult cell, such as a skin or blood cell. iPS cells are pluripotent cells because, like embryonic stem cells, they can develop into virtually any type of cell. iPS cells are distinct from embryonic stem cells, however, because they are derived from adult tissue, rather than from embryos. iPS cells are also distinct from adult stem cells, which naturally occur in small numbers in thehuman body. In 2006, Shinya Yamanaka developed the method for inducing skin cells from mice into becoming like pluripotent stem cells and called them iPS cells. In 2007, Yamanaka did the same with adult human skin cells. Yamanakas experiments revealed that adult skin cells, when treated with four pieces of DNA (now called the Yamanaka factors), can induce skin cells to revert back to their pluripotent state. His discovery has since led to a variety of methods for reprogramming adult cells into stem cells that can become virtually any cell type such as a beating heart cell or a neuron that can transmit chemical signals in the brain. … Continue reading

Posted in Stem Cell Research | Comments Off on Stem Cell Science Q & A

Page 6,421«..1020..6,4206,4216,4226,423..6,4306,440..»